Cargando…

Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure

BACKGROUND: For locally advanced rectal cancer (LARC), standard therapy [consisting of neoadjuvant chemoradiotherapy (CRT), surgery, and adjuvant chemotherapy (ChT)] achieves excellent local control. Unfortunately, survival is still poor due to distant metastases, which remains the leading cause of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tuta, Mojca, Boc, Nina, Brecelj, Erik, Peternel, Monika, Velenik, Vaneja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Clinical and Translational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896420/ https://www.ncbi.nlm.nih.gov/pubmed/33643528 http://dx.doi.org/10.4251/wjgo.v13.i2.119

Ejemplares similares

Total Neoadjuvant Treatment of Locally Advanced Rectal Cancer with High Risk Factors in Slovenia
por: Tuta, Mojca, et al.
Publicado: (2019)

Influence of Concurrent Capecitabine Based Chemoradiotherapy with Bevacizumab on The Survival Rate, Late Toxicity and Health-related Quality of Life in Locally Advanced Rectal Cancer: a Prospective Phase II CRAB Trial
por: Velenik, Vaneja, et al.
Publicado: (2020)

Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer
por: Velenik, Vaneja, et al.
Publicado: (2010)

Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study
por: Velenik, Vaneja, et al.
Publicado: (2011)

Preoperative Intensity-modulated Chemoradiation Therapy with Simultaneous Integrated Boost in Rectal Cancer: 2-year Follow-up Results of Phase II Study
por: But-Hadzic, Jasna, et al.
Publicado: (2018)

Mesenteric ischemia after capecitabine treatment in rectal cancer and resultant short bowel syndrome is not an absolute contraindication for radical oncological treatment
por: Perpar, Ana, et al.
Publicado: (2015)

Induction Chemotherapy, Chemoradiotherapy and Consolidation Chemotherapy in Preoperative Treatment of Rectal Cancer - Long-term Results of Phase II OIGIT-01 Trial
por: Golo, Danijela, et al.
Publicado: (2018)

Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis
por: Kasi, Anup, et al.
Publicado: (2020)

Overstaged Rectal Cancer by MRI due to Fibrosis Induced by Tattoo Marker
por: Gasljevic, Gorana, et al.
Publicado: (2018)

The Influence of the Distal Resection Margin Length on Local Recurrence and long- term Survival in Patients with Rectal Cancer after Chemoradiotherapy and Sphincter- Preserving Rectal Resection
por: Grosek, Jan, et al.
Publicado: (2016)

Cetuximab in preoperative treatment of rectal cancer – term outcome of the XERT trial
por: Velenik, Vaneja, et al.
Publicado: (2012)

Post-treatment surveillance in colorectal cancer
por: Velenik, Vaneja
Publicado: (2010)

Total neoadjuvant therapy for rectal cancer: evidence and challenge
por: Lee, Suk-Hwan
Publicado: (2023)

The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer
por: Oblak, Irena, et al.
Publicado: (2013)

Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials
por: Riesco-Martinez, Maria C., et al.
Publicado: (2020)

Debating Pros and Cons of Total Neoadjuvant Therapy in Rectal Cancer
por: Sclafani, Francesco, et al.
Publicado: (2021)

Total neoadjuvant therapy for rectal cancer: a guide for surgeons
por: Johnson, Garrett G.R.J., et al.
Publicado: (2023)

Preoperative Intensity-modulated Chemoradiotherapy with Simultaneous Integrated Boost in Rectal Cancer: Five-year Follow-up Results of a Phase II Study
por: But-Hadzic, Jasna, et al.
Publicado: (2021)

Total neoadjuvant therapy or standard chemoradiotherapy for locally advanced rectal cancer: A systematic review and meta-analysis
por: Ma, Zhou, et al.
Publicado: (2022)

Total neoadjuvant therapy versus standard therapy in locally advanced rectal cancer: A systematic review and meta-analysis of 15 trials
por: Zhang, Xiping, et al.
Publicado: (2022)

Comparing outcomes following total neoadjuvant therapy and following neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer
por: Zhu, Shaoyu, et al.
Publicado: (2019)

Differences in plasma TIMP-1 levels between healthy people and patients with rectal cancer stage II or III
por: Oblak, Irena, et al.
Publicado: (2011)

Low stromal Foxp3(+) regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer
por: McCoy, M J, et al.
Publicado: (2015)

Total neoadjuvant therapy in locally advanced rectal cancer: Role of systemic chemotherapy
por: Yoo, Ri Na, et al.
Publicado: (2019)

The evolution of rectal cancer treatment: the journey to total neoadjuvant therapy and organ preservation
por: IV, Arthur Affleck, et al.
Publicado: (2022)

Tumor-Infiltrating Neutrophils after Neoadjuvant Therapy are Associated with Poor Prognosis in Esophageal Cancer
por: Cabalag, Carlos S., et al.
Publicado: (2022)

Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy
por: Gash, K J, et al.
Publicado: (2017)

Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview
por: Guida, Andrea M., et al.
Publicado: (2022)

How We Treat Localized Rectal Cancer—An Institutional Paradigm for Total Neoadjuvant Therapy
por: Roeder, Falk, et al.
Publicado: (2022)

Total neoadjuvant therapy in rectal cancer: a network meta-analysis of randomized trials
por: Sychev, Sergey, et al.
Publicado: (2023)

Laparoscopic insertion of pelvic tissue expander prior radiotherapy for sacral metastasis of alveolar maxillary rhabdomyosarcoma to prevent radiation enteritis
por: Omejc, Andrej, et al.
Publicado: (2021)

MRI VS. FDG-PET for diagnosis of response to neoadjuvant therapy in patients with locally advanced rectal cancer
por: Gao, Peng Fei, et al.
Publicado: (2023)

Health-related Quality of Life Assessed by the EORTC QLQ-C30 Questionnaire in the General Slovenian Population
por: Velenik, Vaneja, et al.
Publicado: (2017)

Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer
por: Ramcharan, K S, et al.
Publicado: (2014)

Cost-effectiveness of Total Neoadjuvant Therapy With Short-Course Radiotherapy for Resectable Locally Advanced Rectal Cancer
por: Chin, Re-I, et al.
Publicado: (2022)

Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer
por: Horesh, Nir, et al.
Publicado: (2022)

Does the Gain of Total Neoadjuvant Therapy Outweigh the Harm in Rectal Cancer? Importance of the ATRESS (neoAdjuvant Therapy-RElated Shortening of Survival) Phenomenon: A Systematic Review
por: Socha, Joanna, et al.
Publicado: (2023)

Impact of Perioperative Treatment on Survival of Resectable Gastric Cancer Patients After D2 Lymphadenectomy: A Single European Centre Propensity Score Matching Analysis
por: Jagric, Tomaz, et al.
Publicado: (2019)

Total neoadjuvant treatment in locally advanced rectal cancer
por: De Felice, Francesca, et al.
Publicado: (2021)

Application of Liquid Biopsies in Cancer Targeted Therapy
por: Sumanasuriya, S, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f2hk76tt9bu3oa3eepme8mfke4